[10-Q] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Quarterly Earnings Report
Pacific Biosciences of California, Inc. (PACB) reported Q1 2026 revenue of $37.2 million, flat year-over-year, with higher consumable sales offsetting declines in instrument and service revenue. The company significantly narrowed its net loss to $8.3 million, down from $426.1 million in Q1 2025, largely due to a $45.8 million gain on an asset sale to Illumina and reduced operating expenses. PACB expects sequential revenue growth in Q2 2026 and further improvements in the second half of the year driven by clinical adoption, SPRQ-Nx consumable growth, and its Basecamp Research program.
MAY 1·Traders Union▲
Pacific Biosciences of California presents new AAV workflow to reduce partial snapback genomes
Pacific Biosciences of California has introduced a new heat-then-extract workflow for adeno-associated virus (AAV) genome analysis. This innovative method aims to reduce partial snapback genomes and increase the proportion of full-length genomes, offering significant improvements for researchers in gene therapy and genome sequencing. The company will present these findings at the ASGCT2026 conference, continuing its focus on advancing genome analysis technologies.
APR 29·Yahoo Finance UK→
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) shares closed down 6.96% at $1.47, underperforming the broader S&P 500. The company is set to report earnings on May 7, 2026, with analysts anticipating an EPS of -$0.17 and revenue of $41 million. Despite the recent dip, the stock has gained 19.7% over the past month, and currently holds a Zacks Rank #3 (Hold).
